Alnylam Pharmaceuticals ALNY Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's retained earnings?
- Alnylam Pharmaceuticals (ALNY) reported retained earnings of -$6.33B in Q2 2026.
- How has Alnylam Pharmaceuticals's retained earnings changed year-over-year?
- Alnylam Pharmaceuticals's retained earnings increased by 14.6% year-over-year, from -$7.41B to -$6.33B.
- What is the long-term trend for Alnylam Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's retained earnings has grown at a 7.9% compound annual growth rate (CAGR), from -$4.59B to -$6.7B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.